ID   HepG2S1
AC   CVCL_4W42
DR   Wikidata; Q54882861
RX   PubMed=23111106;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:50924; Sorafenib (Nexavar).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from sampling site: Liver.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 20-05-21; Version: 10
//
RX   PubMed=23111106; DOI=10.1016/j.canlet.2012.10.021;
RA   van Malenstein H., Dekervel J., Verslype C., Van Cutsem E.,
RA   Windmolders P., Nevens F., van Pelt J.F.;
RT   "Long-term exposure to sorafenib of liver cancer cells induces
RT   resistance with epithelial-to-mesenchymal transition, increased
RT   invasion and risk of rebound growth.";
RL   Cancer Lett. 329:74-83(2013).
//